Iressa (AstraZeneca) is withdrawn from US market for NSCLC

Iressa (gefitinib) from AstraZeneca, was granted accelerated approval by the FDA on 2 May 2003 as monotherapy after failure of both platinum-based and docetaxel chemotherapies for the continued treatment of patients with locally advanced or metastatic Non Small Cell Lung Cancer. Postmarketing studies were completed but failed to verify and confirm clinical benefit. The FDA has withdrawn the approval.